^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microtubule inhibitor

    Related drugs:
    2d
    Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=69, Recruiting, Oncomatryx Biopharma S.L.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • OMTX705
    3d
    Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study. (PubMed, Int J Clin Oncol)
    An ALC ≥ 1000/μL at ERI completion was associated with an improved post-ERI OS (OS2). It is suggested that not only the factors at the initiation of ERI, but also the immunological status at the end of ERI, may have prognostic value after ERI.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Halaven (eribulin mesylate)
    3d
    A single-arm, single-center, prospective clinical study of trastuzumab emtansine combined with GEMOX regimen as first-line treatment for advanced biliary system tumors (ChiCTR2600117154)
    P=N/A, N=20, Completed, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New trial
    |
    Kadcyla (ado-trastuzumab emtansine) • Loqtorzi (toripalimab-tpzi)
    3d
    Efficacy and Safety of Becotatug Vedotin (EGFR ADC) plus Pucotenlimab and Cisplatin as Neoadjuvant Therapy for LA-HNSCC (ChiCTR2600115972)
    P=N/A, N=30, Not yet recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    3d
    Mechanistic Exploration and Clinical Impact of Tisotumab Vedotin-Related Adverse Effects: Integrating FAERS Data Mining, Network Pharmacology, Molecular Docking, and Real-World Evidence (ChiCTR2500114973)
    P=N/A, N=20, Not yet recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New trial
    |
    Tivdak (tisotumab vedotin-tftv)
    3d
    This study aims to evaluate the efficacy and safety of Disitamab Vedotin combined with Cisplatin and Candelinib in the treatment of patients with locally advanced cervical cancer. (ChiCTR2500114983)
    P=N/A, N=30, Recruiting, Dalian Medical University Second Affiliated Hospital; Dalian Medical University Second Affiliated Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 expression
    |
    cisplatin • Aidixi (disitamab vedotin) • Kaitanni (cadonilimab)
    3d
    Pucotenlimab Combined with Lenvatinib and eribulin in Patients with Advanced Melanoma Failed in First-Line Therapy, a Single-Arm, Open-Label, Multicenter, Phase II Clinical Study (ChiCTR2500114916)
    P=N/A, N=35, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
    New trial
    |
    Lenvima (lenvatinib) • irinotecan • Halaven (eribulin mesylate) • Puyouheng (pucotenlimab)
    3d
    A single-arm exploratory clinical trial of Utidelone injection for advanced pancreatic cancer refractory to standard therapy (ChiCTR2500112307)
    P=N/A, N=48, Recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    New trial
    |
    utidelone IV (UTD1)
    3d
    Disitamab Vedotin combining with Toripalimab versus adjuvant Toripalimab in HER2 expressed high-risk MIBC patients after radical cystectomy: a prospective, multicentre, open-label, randomised, phase 3 trial (ChiCTR2500111817)
    P3, N=128, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)
    3d
    Disitamab Vedotin combining with BCG intravesical instillation versus BCG in HER2 expressed high-risk NMIBC patients: a prospective, multicentre, randomised, phase 3 trial (Formula-02) (ChiCTR2600117601)
    P3, N=164, Not yet recruiting, Sun Yat-sen University Cancer Center (Sun Yat-Sen University Cancer Center, Sun Yat-sen University Cancer Institute); Sun Yat-sen University Cancer Ce
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Aidixi (disitamab vedotin)
    3d
    Doxorubicin alone versus eribulin with anlotinib followed by anlotinib alone as first-line therapy for metastatic or unresectable L-type sarcoma: a randomised, multicentre,open-label phase 3 trial (ChiCTR2600117706)
    P3, N=120, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P3 trial
    |
    Focus V (anlotinib) • doxorubicin hydrochloride • Halaven (eribulin mesylate)
    3d
    Disitamab Vedotin combining with Toripalimab versus adjuvant Toripalimab in HER2 expressed locally advanced UTUC patients after nephron-ureterectory: a prospective, multicentre, open-label, randomised, phase 3 trial (ChiCTR2500115471)
    P3, N=106, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)